Efficacy of Zinc-L-Carnosine (Polaprezinc) in Treating Infant Regurgitation: Results from a Two-Center Randomized Controlled Study - Scorecard - MDSpire

Efficacy of Zinc-L-Carnosine (Polaprezinc) in Treating Infant Regurgitation: Results from a Two-Center Randomized Controlled Study

  • By

  • Marisa Piccirillo

  • Maurizio Mennini

  • Enrico Felici

  • Angela Mauro

  • Luca Bernardo

  • Maria Elisabetta Baldassarre

  • Erika Renzi

  • Corrado De Vito

  • Silvia Furio

  • Marco Graziani

  • Giovanna Quatrale

  • Alessandro Ferretti

  • Giovanni Di Nardo

  • April 21, 2026

  • 0 min

Share

Clinical Scorecard: Efficacy of Zinc-L-Carnosine (Polaprezinc) in Treating Infant Regurgitation: Results from a Two-Center Randomized Controlled Study

At a Glance

CategoryDetail
ConditionGastroesophageal reflux (GER) in infants
Key MechanismsZinc-L-carnosine (Polaprezinc) acts as a mucosal protectant with anti-inflammatory and antioxidant properties.
Target PopulationInfants aged 4 weeks to 7 months with persistent regurgitation
Care SettingPediatric hospitals

Key Highlights

  • Zinc-L-carnosine is a safe and effective alternative to thickened formula.
  • Significant improvement in I-GERQ-R scores observed at 8 weeks.
  • Greater reduction in regurgitation frequency in the Hepilor liquido® group.
  • Average treatment cost was significantly lower in the Hepilor liquido® group.
  • No severe adverse events recorded in either treatment group.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis based on Rome IV criteria for infant regurgitation.

Management

  • Non-pharmacological measures should be attempted before pharmacological interventions.

Monitoring & Follow-up

  • Monitor symptom improvement using the I-GERQ-R questionnaire.

Risks

  • Exclusion of infants with severe symptoms or chronic diseases.

Patient & Prescribing Data

Infants aged 4 weeks to 7 months with persistent regurgitation.

Hepilor liquido® (Zinc-L-carnosine) shows promise as a cost-effective treatment option.

Clinical Best Practices

  • Adopt non-pharmacological approaches before initiating treatment.
  • Use validated questionnaires like I-GERQ-R for assessing symptom severity.

References

Original Source(s)

Efficacy of Zinc-L-Carnosine (Polaprezinc) in Treating Infant Regurgitation: Results from a Two-Center Randomized Controlled Study

  • by Marisa Piccirillo, Maurizio Mennini, Enrico Felici, Angela Mauro, Luca Bernardo, Maria Elisabetta Baldassarre, Erika Renzi, Corrado De Vito, Silvia Furio, Marco Graziani, Giovanna Quatrale, Alessandro Ferretti, Giovanni Di Nardo

  • April 21, 2026

Related Content

Roux-en-Y Gastric Bypass and Sleeve Gastrectomy Risk-Adjusted Safety Profiles after Previous Fundoplication: A 499-Patient MBSAQIP Analysis

Comparative study of midterm outcomes between Roux-en-Y gastric bypass (RYGB), diverted one-anastomosis gastric bypass (D-OAGB), and one anastomosis gastric bypass (OAGB)

A safety and effectiveness evaluation of RefluxStop in the treatment of acid reflux comparing large and small hiatal hernia groups: results from 99 patients in Switzerland with up to 4-years follow-up